Dworkowitz Quoted on Proposed Rule Promoting Value-Based Drug Pricing in Medicaid

Manatt Health partner Alexander Dworkowitz spoke with MedPage Today and Bloomberg Law about the Centers for Medicare & Medicaid Services’ proposed rule that offers financial protections for drug companies entering contracts with state Medicaid plans and commercial plans based on the value of a drug. In particular, Dworkowitz discussed how this proposal lowers the risk drug companies face when deciding the price they will charge for a medication. “The hope is that more companies will use outcome-based payments if there’s less financial risk. Just because a drug didn’t work for one person, you don’t have to give the same discount for a million other people [under this policy],” he told Bloomberg Law.

Dworkowitz was also quoted in Dark Daily on this development.



pursuant to New York DR 2-101(f)

© 2022 Manatt, Phelps & Phillips, LLP.

All rights reserved